EX-FILING FEES 4 d742117dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Form S-3

(Form Type)

Catalyst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

 

                         
    

Security

Type

 

Security

Class

Title

  Fee
Calculation
or Carry
Forward
Rule
 

Amount

Registered (1)

  Proposed
Maximum
Offering
Price Per
Unit (2)
 

Maximum
Aggregate
Offering

Price

 

Fee

Rate

 

Amount of
Registration

Fee

  Carry
Forward
Form
Type
  Carry
Forward
File
Number
  Carry
Forward
Initial
Effective
Date
  Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities
               
    Primary Offering of Securities:              
                         

Fees to be

Paid

  Equity   Common Stock, par value $0.001 per share (3)   457(r)   $—   $—   $—     $—        
                         

Fees to be

Paid

  Equity   Preferred Stock, par value $0.001 per share (4)   457(r)   $—   $—   $—     $—        
                         

Fees to be

Paid

  Equity   Warrants (5)   457(r)   $—   $—   $—     $—        
                         

Fees to be

Paid

  Debt   Debt Securities (6)   457(r)   $—   $—   $—     $—        
                         

Fees to be

Paid

  Other   Units (7)   457(r)   $—   $—   $—     $—        
                         

Fees to be

Paid

  Unallocated (Universal) Shelf   (1)   457(o)   $500,000,000   $—   $500,000,000   0.0001102   $55,100        
                         

Fees to be

Paid

  Total Registration Fee       $500,000,000   N/A   $500,000,000   0.0001102   $55,100        
 
Carry Forward Securities
                         

Carry

Forward

Securities

                       
                   
    Total Offering Amounts      $500,000,000     $55,100          
                   
    Total Fees Previously Paid                   
                   
    Total Fee Offsets          $25,960 (8)          
                   
    Net Fee Due                $29,140 (8)                

 

(1)

The amount to be registered consists of $500,000,000 of common stock, preferred stock, warrants, debt securities and/or units. There is also being registered hereunder such currently indeterminate amount of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of preferred stock, common stock, debt securities or units as may be issued upon exercise of warrants registered hereby, including any applicable antidilution provisions. Any securities registered hereunder may be sold separately or together with other securities registered hereunder.

(2)

The proposed maximum offering price per security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

(3)

Including such indeterminate amount of common stock as may be issued from time to time at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(4)

Including such indeterminate amount of preferred stock as may be issued from time to time by the registrant at indeterminate prices or upon conversion of debt securities and/or preferred stock registered hereby, or upon exercise of warrants registered hereby, as the case may be.

(5)

Warrants may be sold separately or together with any of the securities registered hereby and may be exercisable for shares of common stock or preferred stock registered hereby. Because the warrants will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(6)

Including such indeterminate principal amount of debt securities as may be issued from time to time at indeterminate prices or upon exercise of warrants registered hereby, as the case may be.

(7)

Each unit will be issued under a unit agreement and will represent an interest in one or more securities registered pursuant to this registration statement, which may or may not be separable from one another. Because the units will provide a right only to purchase such securities offered hereunder, no additional registration fee is required.

(8)

On July 23, 2020, the registrant filed a Shelf Registration Statement on Form S-3, File No. 333-240052 (the “Prior Registration Statement”), which registered and offered the sale of up to $200,000,000 of common stock, preferred stock, warrants, debt securities and/or units, all of which remain unsold (the “Unsold Securities”). Pursuant to Rule 457(p) under the Securities Act, the registrant hereby applies the previously paid registration fee in connection with the Prior Registration Statement in connection with the Unsold Securities to offset the registration of securities on this registration statement. Pursuant to Rules 415(a)(5) and 457(p) under the Securities Act, the offering of the Unsold Securities has expired and thus all offerings under the Prior Registration Statement have been completed.


Table 2: Fee Offset Claims and Sources

 

                       
    

Registrant

or Filer

Name

  Form
or
Filing
Type
 

File

Number

 

Initial

Filing

Date

 

Filing

Date

 

Fee

Offset
Claimed

 

Security

Type

Associated

with Fee

Offset

Claimed

 

Security

Title

Associated

with Fee

Offset

Claimed

 

Unsold

Securities
Associated

with Fee

Offset

Claimed

 

Unsold

Aggregate
Offering

Amount
Associated

with Fee

Offset

Claimed

 

Fee

Paid

with

Fee

Offset
Source

 
Rule 457(p)
                       

Fee Offset

Claims

  Catalyst Pharmaceuticals, Inc.   S-3   333-240052   July 23, 2020     $25,960   Unallocated (Universal) Shelf   Unallocated (Universal) Shelf (1)   $200,000,000   $200,000,000  
                       

Fee Offset

Sources

  Catalyst Pharmaceuticals, Inc.   S-3   333-240052     July 23, 2020     Unallocated (Universal) Shelf         $25,960

 

(1)

See Note (1) under Table 1 above.